Evert Kueppers appointed CEO and co-founder Dr Lilian Walther Jallow transitioned to Chief Development Officer.
Significant progress seen for ongoing BOOSTB4 clinical study.
February 1, 2022
Leadership and clinical update
< Back to Updates
February 1, 2022
Evert Kueppers appointed CEO and co-founder Dr Lilian Walther Jallow transitioned to Chief Development Officer.
Significant progress seen for ongoing BOOSTB4 clinical study.
< Back to Updates